Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127905841 | 12790584 | 1 | I | 20111130 | 20120207 | 20160929 | 20160929 | EXP | US-ROCHE-1038196 | ROCHE | 56.00 | YR | F | Y | 68.80000 | KG | 20160929 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127905841 | 12790584 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | OVER 30-90 MINUTES ON DAYS 1 AND 15 | Y | 125085 | 1440 | MG | SOLUTION FOR INFUSION | ||||||
| 127905841 | 12790584 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 1440 | MG | SOLUTION FOR INFUSION | |||||||
| 127905841 | 12790584 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 1440 | MG | SOLUTION FOR INFUSION | |||||||
| 127905841 | 12790584 | 4 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | ON DAYS 1, 8, 15, AND 22 | Y | 0 | 100 | MG | |||||||
| 127905841 | 12790584 | 5 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 75 | MG | ||||||||
| 127905841 | 12790584 | 6 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 80 | MG | ||||||||
| 127905841 | 12790584 | 7 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 60 | MG | ||||||||
| 127905841 | 12790584 | 8 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 30 | MG | ||||||||
| 127905841 | 12790584 | 9 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 30 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127905841 | 12790584 | 1 | Malignant neoplasm of islets of Langerhans |
| 127905841 | 12790584 | 4 | Malignant neoplasm of islets of Langerhans |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127905841 | 12790584 | HO |
| 127905841 | 12790584 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127905841 | 12790584 | Abdominal infection | |
| 127905841 | 12790584 | Diarrhoea | |
| 127905841 | 12790584 | Fatigue | |
| 127905841 | 12790584 | Hyperglycaemia | |
| 127905841 | 12790584 | Hypokalaemia | |
| 127905841 | 12790584 | Hyponatraemia | |
| 127905841 | 12790584 | Hypophosphataemia | |
| 127905841 | 12790584 | Wound dehiscence |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127905841 | 12790584 | 1 | 20111019 | 0 | ||
| 127905841 | 12790584 | 2 | 20111116 | 0 | ||
| 127905841 | 12790584 | 3 | 20111214 | 0 | ||
| 127905841 | 12790584 | 4 | 20111019 | 0 | ||
| 127905841 | 12790584 | 5 | 20111116 | 0 | ||
| 127905841 | 12790584 | 6 | 20111214 | 0 | ||
| 127905841 | 12790584 | 7 | 20120102 | 0 | ||
| 127905841 | 12790584 | 8 | 20120129 | 0 | ||
| 127905841 | 12790584 | 9 | 20120411 | 0 |